Agenus is a biotechnology company that researches and develops novel antibodies and vaccines for the treatment of cancer.
Business Model:
Revenue: $89.9M
Employees: 201-500
Address: 3 Forbes Road
City: Lexington
State: MA
Zip: 02421-7305
Country: US
Agenus is a biotechnology company that researches and develops novel antibodies and vaccines for the treatment of cancer.
Contact Phone:
+17816744400
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
2/11/2000
IPO Valuation:
$436M
Ticker Symbol:
AGEN
IPO Price:
$18/share
Amount Raised:
$63M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2019 | Post-IPO Equity | $30M | 12/2015 | Post-IPO Equity | $500k | 5/2020 | Debt | $2M |
U.S. Small Business Administration. |
9/2015 | Post-IPO Debt | $100M | 3/2015 | Post-IPO Equity | $35M | 8/2009 | Post-IPO Equity | $0 |
Iroquois Capital Hudson Capital Group Downsview Capital Iroquois Capital Hudson Capital Group Downsview Capital |
2/2017 | Post-IPO Equity | $0 |
Incyte Incyte |
4/2013 | Post-IPO Debt | $5M | 3/2015 | Post-IPO Debt | $21.1M | 10/2018 | Post-IPO Equity | $40M | 2/2017 | Post-IPO Equity | 1 | $60M |
Incyte |
8/2009 | Post-IPO Equity | 3 | $10M |
Iroquois Capital Hudson Capital Group Downsview Capital Iroquois Capital Hudson Capital Group Downsview Capital |
---|
Announced Date | Name | Price |
---|---|---|
12/2015 | PhosImmune | |
4/2015 | Celexion | |
1/2014 | 4-Antibody AG |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|